Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...

Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor, ...

Two canine osteosarcoma patients who underwent amputations are shown in 2023, when their care team and owners celebrated their final chemo treatments by ringing a bell and giving both dogs lots of ...

(RTTNews) - OS Therapies Inc. (OSTX) Thursday announced positive data for OST-HER2 in combination with palliative radiation in dogs with unresected appendicular osteosarcoma. Results from the study ...

Researchers from UC Davis and Lawrence Livermore National Laboratory developed and studied a new material — engineered bone marrow, or eBM. Engineered bone marrow offers a better way to study ...